新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » CRO/CMO » 异军突起,药明康德悄然在美开建免疫疗法产品工厂

异军突起,药明康德悄然在美开建免疫疗法产品工厂

来源:生物谷 2015-03-13 13:09

2015年3月13日讯 /生物谷BIOON/--如果问最近几年生物医药产业最火的是什么?那么肿瘤免疫疗法一定位于这个榜单上的前三之列。

近几年来随着科学家对人体免疫系统以及肿瘤发生机制认识的深入,医药产业涌现出了一大批前景光明的肿瘤免疫疗法。这些疗法得到了从医药公司到华尔街投资者以及FDA审查人员的高度重视。而随着几年的发展,许多肿瘤免疫疗法也已经处于临床三期研究阶段,在不久的将来,世界生物医药产业即将会迎来一个肿瘤免疫疗法上市的井喷期。

有鉴于此,中国著名的CRO药明康德公司最近宣布,公司计划在美国宾州费城建立一处占地面积达到145000平方英尺的工厂,这处工厂未来将专门用于生产以CAR-T为代表的肿瘤免疫疗法产品。这也将是药明康德开建的第三处专门用于生产细胞疗法相关产品的工厂。

药明康德将为医药公司提供这些药物生产加工服务。预计药明康德公司位于费城的这处厂家将于2016年中期完工,届时公司用于细胞疗法相关产品生产的工厂面积将从现有的16,000平方英尺激增至206,000平方英尺。

一直以来,从医药公司到产业人士和投资家们的关注重点似乎都集中在肿瘤免疫疗法的开发进程中,而这也导致了巨量的资金和人力在这一领域的上游过度集中。如今,药明康德异军突起,下大力气建设下游生产设备,可以称得上是一步妙棋。(生物谷Bioon.com)

相关会议推荐

 

新一届的肿瘤与免疫治疗研讨会将在往届的讨论基础上,增加肿瘤免疫治疗、深度测序、非编码RNA与肿瘤发生、肿瘤干细胞与靶向治疗策略、肿瘤细胞自噬、肿瘤临床多中心与多学科协作研究等内容。我们真诚地邀请活跃在肿瘤基础和转化医学研究第一线的科学和临床工作者与会,见证肿瘤研究领域中的最新突破性理论和技术上的进展,共商开展国际水平的肿瘤转化医学研究的大计。

详细英文报道:

SHANGHAI, March 12, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, announced today that it will soon begin construction of a new, 145,000-square-foot cGMP facility in Philadelphia for the manufacture of cell therapy products. This facility is designed for cell therapy products that contain viral vectors such as chimeric antigen receptor T cell (CAR T cell) therapies. CAR T cells are T cells harvested from a patient's body, engineered to target specific cancers, and then reintroduced into the body.

The new facility will become WuXi's third cell therapy manufacturing facility when it becomes operational by mid-2016. It will provide single-source contract development and cGMP manufacturing capabilities to support the rapidly growing cellular therapeutic industry's unique requirements. Specifically, the new facility will provide manufacturing capability and capacity to meet the rapidly expanding demand for clinical studies and commercial supply. The new facility will expand upon WuXi's existing 16,000-square-foot cGMP cell therapy manufacturing facility, as well as a 45,000-square-foot facility for the manufacturing of allogeneic and autologous cell-based therapeutics that is expected to be completed by mid-2015. By 2016, WuXi's available manufacturing capacity in the U.S. of 206,000 square feet would help meet the anticipated market needs of clinical and commercial production for cell-therapy companies. These facilities will complement the company's current fully integrated facility for biological safety and lot release testing in Philadelphia.

"Cell therapies like CAR T cells offer important new treatment options for cancer patients, and WuXi aims to be at the forefront of this area of providing our partners with cutting-edge cGMP manufacturing capabilities and capacities," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库